Drug-eluting stent implantation for coronary artery disease: current stents and a comparison with bypass surgery

Stuart Head; Ad Bogers; Arie-Pieter Kappetein

doi:10.1016/j.coph.2012.01.003

Drug-eluting stent implantation for coronary artery disease: current stents and a comparison with bypass surgery

Stuart Head, Ad Bogers, Arie-Pieter Kappetein

Cardiothoracic Surgery

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

Abstract

Percutaneous coronary intervention (PCI) with bare-metal stents (BMS) has been performed increasingly ever since its introduction in the late 1970s. BMS have been replaced by drug-eluting stents (DES), and many interventional cardiologists consider this as a breakthrough therapy that might compete with coronary artery bypass grafting (CABG) as the standard treatment for coronary artery disease. Several DES are currently used and elute different agents. This review described what these agents are and provides an overview regarding the outcomes and associated adverse events. More importantly, this review compares outcomes of PCI with DES to CABG for patients with left anterior descending coronary artery involvement, left main involvement, or multivessel disease.

Original language	Undefined/Unknown
Pages (from-to)	147-154
Number of pages	8
Journal	Current Opinion in Pharmacology
Volume	12
Issue number	2
DOIs	https://doi.org/10.1016/j.coph.2012.01.003
Publication status	Published - 2012

Research programs

EMC COEUR-09

Access to Document

10.1016/j.coph.2012.01.003

http://hdl.handle.net/1765/56492

Cite this

@article{4534fea895df4f8aad4d07d80dff6107,

title = "Drug-eluting stent implantation for coronary artery disease: current stents and a comparison with bypass surgery",

abstract = "Percutaneous coronary intervention (PCI) with bare-metal stents (BMS) has been performed increasingly ever since its introduction in the late 1970s. BMS have been replaced by drug-eluting stents (DES), and many interventional cardiologists consider this as a breakthrough therapy that might compete with coronary artery bypass grafting (CABG) as the standard treatment for coronary artery disease. Several DES are currently used and elute different agents. This review described what these agents are and provides an overview regarding the outcomes and associated adverse events. More importantly, this review compares outcomes of PCI with DES to CABG for patients with left anterior descending coronary artery involvement, left main involvement, or multivessel disease.",

author = "Stuart Head and Ad Bogers and Arie-Pieter Kappetein",

year = "2012",

doi = "10.1016/j.coph.2012.01.003",

language = "Undefined/Unknown",

volume = "12",

pages = "147--154",

journal = "Current Opinion in Pharmacology",

issn = "1471-4892",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Drug-eluting stent implantation for coronary artery disease: current stents and a comparison with bypass surgery

AU - Head, Stuart

AU - Bogers, Ad

AU - Kappetein, Arie-Pieter

PY - 2012

Y1 - 2012

N2 - Percutaneous coronary intervention (PCI) with bare-metal stents (BMS) has been performed increasingly ever since its introduction in the late 1970s. BMS have been replaced by drug-eluting stents (DES), and many interventional cardiologists consider this as a breakthrough therapy that might compete with coronary artery bypass grafting (CABG) as the standard treatment for coronary artery disease. Several DES are currently used and elute different agents. This review described what these agents are and provides an overview regarding the outcomes and associated adverse events. More importantly, this review compares outcomes of PCI with DES to CABG for patients with left anterior descending coronary artery involvement, left main involvement, or multivessel disease.

AB - Percutaneous coronary intervention (PCI) with bare-metal stents (BMS) has been performed increasingly ever since its introduction in the late 1970s. BMS have been replaced by drug-eluting stents (DES), and many interventional cardiologists consider this as a breakthrough therapy that might compete with coronary artery bypass grafting (CABG) as the standard treatment for coronary artery disease. Several DES are currently used and elute different agents. This review described what these agents are and provides an overview regarding the outcomes and associated adverse events. More importantly, this review compares outcomes of PCI with DES to CABG for patients with left anterior descending coronary artery involvement, left main involvement, or multivessel disease.

U2 - 10.1016/j.coph.2012.01.003

DO - 10.1016/j.coph.2012.01.003

M3 - Article

C2 - 22285216

SN - 1471-4892

VL - 12

SP - 147

EP - 154

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

IS - 2

ER -